The current stock price of NXTM is 30 null. In the past month the price increased by 5.49%. In the past year, price increased by 27.71%.
ChartMill assigns a technical rating of 9 / 10 to NXTM. When comparing the yearly performance of all stocks, NXTM is one of the better performing stocks in the market, outperforming 87.3% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to NXTM. NXTM has an average financial health and profitability rating.
Over the last trailing twelve months NXTM reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 61.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1.29% | ||
| ROA | -1.46% | ||
| ROE | -2.44% | ||
| Debt/Equity | 0 |
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.
NXSTAGE MEDICAL INC
350 MERRIMACK STREET
LAWRENCE MA 01843
CEO: Jeffrey H. Burbank
Phone: 978-687-4700
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.
The current stock price of NXTM is 30 null. The price increased by 0.03% in the last trading session.
NXTM does not pay a dividend.
NXTM has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
NXSTAGE MEDICAL INC (NXTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
NXSTAGE MEDICAL INC (NXTM) has a market capitalization of 2.00B null. This makes NXTM a Mid Cap stock.